NICE widens access to Alexion’s Strensiq
Alexion Pharma and the National Institute for Health and Care Excellence have come to a new arrangement that widens NHS access to Strensiq for people with paediatric-onset hypophosphatasia.
Read More
Tag: Strensiq
NICE restricts NHS access to Alexion’s £366K-a-year bone drug
The National Institute for Health and Care Excellence has published draft guidelines that restrict the use of Alexion’s £366,912-a-year enzyme replacement therapy Strensiq by the National Health Service in treating patients with hypophosphatasia.
Read More
NICE backs restricted use of Alexion’s Strensiq
Cost regulators for NHS treatments in England and Wales have recommended use of Alexion’s Strensiq to treat a rare and often fatal condition called hypophosphatasia (HPP), but have restricted its reach to children with certain forms of the condition.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
